FAM
AKRO

Fred Alger Management’s Akero Therapeutics AKRO Stock Holding History

Fred Alger Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-142,247
Closed -$6.75M – 463
2025
Q3 		$6.75M Sell
142,247
-168,322
-54% -$8.15M 0.03% 209
2025
Q2 		$16.6M Sell
310,569
-204,755
-40% -$9.3M 0.07% 128
2025
Q1 		$20.9M Buy
515,324
+251,971
+96% +$10.7M 0.12% 107
2024
Q4 		$7.33M Sell
263,353
-6,248
-2% -$189K 0.03% 205
2024
Q3 		$7.73M Buy
269,601
+145,813
+118% +$3.8M 0.04% 206
2024
Q2 		$2.9M Sell
123,788
-1,213,093
-91% -$25.9M 0.01% 296
2024
Q1 		$33.8M Buy
1,336,881
+1,246,069
+1,372% +$29.9M 0.17% 110
2023
Q4 		$2.12M Sell
90,812
-350,274
-79% -$6.91M 0.01% 326
2023
Q3 		$22.3M Buy
441,086
+427,303
+3,100% +$19.9M 0.13% 138
2023
Q2 		$644K Buy
+13,783
New +$632K ﹤0.01% 389
2022
Q4 		– Sell
-11,981
Closed -$408K – 517
2022
Q3 		$408K Buy
+11,981
New +$183K ﹤0.01% 404

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fred Alger Management's AKRO Position: Q4 2025 in Review

Fred Alger Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 142,247 shares — an estimated $6.75M sold.

Fred Alger Management first reported a position in AKRO in Q3 2022 and held it in 11 quarters. The position peaked at $33.8M in Q1 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Fred Alger Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fred Alger Management sold 142,247 Akero Therapeutics shares in Q4 2025, an estimated $6.75M.
  • Fred Alger Management first reported a position in Akero Therapeutics in Q3 2022 and held it in 11 quarters.
  • Fred Alger Management's Akero Therapeutics position peaked at $33.8M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Fred Alger Management's 13F filing for Q4 2025, filed 17 Feb 2026.